Waldenstrom's macroglobulinaemia recurrent

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
BTK inhibitor 1 substance
Phase II: 1 Phase I: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Acerta Pharma B.V. Commercial
    ACALABRUTINIB
    2023-509356-34-00 3 countries 2015 n=6
    Ended

Phase I

1 trial
  • Ubix Therapeutics Inc. Commercial
    IMP not specified
    2023-510484-35-00 1 country n=42
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ubix Therapeutics Inc. Commercial 1 Phase I 0
Acerta Pharma B.V. Commercial 1 Phase II 0
← All indication landscapes